The U.S. Food and Drug Administration (FDA) recently published a new Guidance for Industry, titled ANDAs: Stability Testing of Drug Substances and Products, Questions and Answers, which provides answers to questions from public comments received on the draft Guidance for Industry on ANDAs: Stability Testing of Drug Substances and Products ("FDA stability guidance") that was published in the Federal Register on September 25, 2012. It also incorporates comments received on the same draft, which were previously published in the Federal Register on August 27, 2013.
As an initial matter, FDA guidance documents—including the guidance document included with this Alert—do not create legally enforceable rights or responsibilities. Rather, this guidance only represents FDA's current thinking on a topic, and should be read only as containing recommendations, unless specific regulatory or statutory requirements are cited.
In summary, the attached guidance addresses issues related to drug master files (DMFs) and drug product manufacturing and packaging. It also includes a discussion of stability studies, which is intended to clarify the stability testing data recommendations for abbreviated new drug applications (ANDAs).
The final FDA stability guidance covers all new ANDAs under the Federal Food, Drug, and Cosmetic Act, section 505(j) and DMFs (Type II for drug substances that support the ANDAs). The final guidance was published on June 20, 2013, with an implementation date of June 20, 2014. It does not apply to postapproval changes.
If you have any questions about this Alert, please contact Frederick (Rick) R. Ball, Emily N. Winfield, any member of the Pharmaceutical, Medical Device, Pharmacy & Food industry group or the attorney in the firm with whom you are regularly in contact.
This article is for general information and does not include full legal analysis of the matters presented. It should not be construed or relied upon as legal advice or legal opinion on any specific facts or circumstances. The description of the results of any specific case or transaction contained herein does not mean or suggest that similar results can or could be obtained in any other matter. Each legal matter should be considered to be unique and subject to varying results. The invitation to contact the authors or attorneys in our firm is not a solicitation to provide professional services and should not be construed as a statement as to any availability to perform legal services in any jurisdiction in which such attorney is not permitted to practice.
Duane Morris LLP, a full-service law firm with more than 700 attorneys in 24 offices in the United States and internationally, offers innovative solutions to the legal and business challenges presented by today's evolving global markets. Duane Morris LLP, a full-service law firm with more than 700 attorneys in 24 offices in the United States and internationally, offers innovative solutions to the legal and business challenges presented by today's evolving global markets. The Duane Morris Institute provides training workshops for HR professionals, in-house counsel, benefits administrators and senior managers.
